一例前列腺癌患者中18F-FDG PET/CT与68Ga-PSMA PET/CT检测药物相关性颌骨坏死的比较
本文报告一例65岁前列腺癌患者在接受唑来膦酸治疗后发生药物相关性颌骨坏死(ONJ),18F-FDG PET/CT显示ONJ代谢活性高,而68Ga-PSMA PET/CT未见PSMA受体激活;作者强调在接受唑来膦酸治疗的患者中,18F-FDG PET/CT成像对药物相关性ONJ的重要性,以及可提供快速适当的治疗。
要点
- 药物相关性颌骨坏死是唑来膦酸的罕见不良反应。
- 18F-FDG PET/CT上ONJ代谢活性高,68Ga-PSMA PET/CT上无PSMA受体激活。
- 作者强调在接受唑来膦酸治疗的患者中,18F-FDG PET/CT成像对药物相关性ONJ的重要性。
核心结论
- 作者强调在接受唑来膦酸治疗的患者中,18F-FDG PET/CT成像对药物相关性ONJ的重要性,并强调可提供快速适当的治疗。
研究设计与样本
- 本文报告一例65岁前列腺癌患者,接受18F-FDG PET/CT以进行代谢表征并排除68Ga-PSMA PET/CT所见的肝脏病灶为第二原发恶性肿瘤。
主要发现
- ONJ在18F-FDG PET/CT上显示高代谢活性,在68Ga-PSMA PET/CT上无PSMA受体激活。
临床怎么用
- 作者强调在接受唑来膦酸治疗的患者中,18F-FDG PET/CT成像对药物相关性ONJ的重要性,并强调可提供快速适当的治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Medication-related osteonecrosis of the jaw (ONJ) is rare adverse effect of zoledronic acid. We present ONJ detected in a 65-year-old man with prostate cancer who underwent 18 F-FDG PET/CT for metabolic characterization and to exclude a second primary malignancy of the liver lesion observed in 68 Ga-PSMA PET/CT. ONJ has high metabolic activity on 18 F-FDG PET/CT and no PSMA receptor activation on the 68 Ga-PSMA PET/CT. In this case, we wanted to underline the importance of 18 F-FDG PET/CT imaging of medication-related ONJ in patients receiving zoledronic acid therapy and to emphasize that rapid and appropriate treatment can be provided.
引用
- Öztürk AE, Şahin R, Ergül N, et al. A Comparison of 18 F-FDG PET/CT and 68 Ga-PSMA PET/CT in Detecting Osteonecrosis of the Jaw in a Patient With Prostate Cancer. Clin Nucl Med. 2023. PMID: 38170920. doi:10.1097/RLU.0000000000004970
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。